TY - JOUR
T1 - Toward a new molecular taxonomy of diffuse large b-cell lymphoma
AU - Ennishi, Daisuke
AU - Hsi, Eric D.
AU - Steidl, Christian
AU - Scott, David W.
N1 - Funding Information:
C. Steidl is a consultant at Seattle Genetics, Curis Inc., Roche, AbbVie, Juno Therapeutics, and Bayer and reports receiving commercial research grants from Bristol-Myers Squibb and Trillium Therapeutics Inc. D.W. Scott is a consultant at AbbVie, Janssen, and Celgene, reports receiving commercial research grants from Janssen, NanoString, and Roche/Genentech, and has ownership interest in patents for identifying molecular subtypes of lymphoma. One of these patents is licensed to NanoString. No potential conflicts of interest were disclosed by the other authors.
Funding Information:
D. Ennishi, C. Steidl, and D.W. Scott acknowledge the support of the BC Cancer Foundation. C. Steidl is a recipient of a Michael Smith Foundation for Health Research Career Investigator award. D.W. Scott is a recipient of a Michael Smith Foundation for Health Research Health Professional-Investigator award.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020
Y1 - 2020
N2 - Diffuse large B-cell lymphoma (DLBCL) represents a grouping of clinically and biologically heterogeneous tumors. Application of advanced molecular technology has significantly expanded our knowledge of DLBCL pathobiology, allowing identification of subgroups with common, potentially targetable, biological themes. Here, we review the recent molecular analyses that could provide a paradigm shift to a new taxonomy, foundational to the rational transition to pre-cision medicine. We discuss how classification systems may be synthesized into a common taxonomy, drawing strength from the relationships between genetic alterations, gene expression, and tumor microenvironment. Finally, challenges to translating such a taxonomy to the clinic will be outlined.
AB - Diffuse large B-cell lymphoma (DLBCL) represents a grouping of clinically and biologically heterogeneous tumors. Application of advanced molecular technology has significantly expanded our knowledge of DLBCL pathobiology, allowing identification of subgroups with common, potentially targetable, biological themes. Here, we review the recent molecular analyses that could provide a paradigm shift to a new taxonomy, foundational to the rational transition to pre-cision medicine. We discuss how classification systems may be synthesized into a common taxonomy, drawing strength from the relationships between genetic alterations, gene expression, and tumor microenvironment. Finally, challenges to translating such a taxonomy to the clinic will be outlined.
UR - http://www.scopus.com/inward/record.url?scp=85100263673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100263673&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-20-0174
DO - 10.1158/2159-8290.CD-20-0174
M3 - Article
C2 - 32616477
AN - SCOPUS:85100263673
VL - 10
SP - 1267
EP - 1281
JO - Cancer Discovery
JF - Cancer Discovery
SN - 2159-8274
IS - 9
ER -